Table 2.
Estimated absolute risk difference (percentage points) between goserelin and no goserelin for four outcomes
| Women who did not take tamoxifen (n = 945) |
Women who took tamoxifen (n = 1761) |
|||
| No. of years after randomization | Absolute risk difference* (95% confidence interval) | Number needed to treat† | Absolute risk difference (95% confidence interval) | Number needed to treat |
| Any event (recurrence, new tumor, or death) | ||||
| 5 | −10.7 (−14.7 to −6.0) | 9 | −1.9 (−5.1 to 1.4) | 53 |
| 10 | −12.8 (−17.7 to −7.0) | 8 | −2.5 (−6.8 to 1.8) | 40 |
| 15 | −13.9 (−19.4 to −7.5) | 7 | −2.8 (−7.7 to 2.0) | 36 |
| Death from any cause | ||||
| 5 | −4.6 (−7.1 to −1.4) | 23 | −1.3 (−3.4 to 1.1) | 77 |
| 10 | −7.6 (−11.9 to −2.3) | 13 | −2.1 (−5.6 to 1.8) | 48 |
| 15 | −9.2 (−14.4 to −2.7) | 11 | −2.5 (−6.8 to 2.2) | 40 |
| Breast cancer recurrence | ||||
| 5 | −10.1 (−14.3 to −5.4) | 10 | −1.9 (−5.0 to 1.4) | 53 |
| 10 | −11.9 (−17.1 to −6.4) | 8 | −2.5 (−6.6 to 1.9) | 40 |
| 15 | −12.8 (−18.4 to −6.8) | 8 | −2.8 (−7.5 to 2.1) | 36 |
| Death from breast cancer | ||||
| 5 | −4.4 (−7.0 to −1.2) | 23 | −1.3 (−3.3 to 1.1) | 77 |
| 10 | −7.3 (−11.7 to −1.9) | 14 | −2.2 (−5.4 to 1.7) | 45 |
| 15 | −8.5 (−13.7 to −2.2) | 12 | −2.6 (−6.6 to 2.1) | 38 |
*
If P is the event rate in the no goserelin arm (eg, EFS rate or risk of recurrence) at a specified time point, then the absolute difference at this time is P − exp[hazard ratio × logeP ]. The hazard ratios were taken from Table 1 (tamoxifen = “No” or “Yes”).
†
Number needed to treat = 100% (absolute risk difference). The expected number of women who need to be treated with goserelin to avoid one event at the specified time point.